Estados Unidos · Plataformas y datos · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Publicado por TipRanks · Estados Unidos hace 17 h

Resumen detallado

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

Leer el artículo completo en TipRanks Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.tipranks.com)

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Resumen detallado

También te puede interesar

Insider Buying: Hudson Pacific Properties (NYSE:HPP) President Purchases $43,650.00 in Stock

3 Magnificent Stocks to Buy Before 2027 and Hold for a Decade

'Scrooge' collects $19M, finds weekend receipts surprisingly festive

‘We had the worst fight’: I want my husband to retire at 65, but I don’t want to lose his $280,000 salary. Is that unreasonable?

Prediction: When Will Bitcoin Get Back to Its All-Time High?

Veteran trader warns Bitcoin's record may outlive him

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Resumen detallado

Compartir

También te puede interesar

Insider Buying: Hudson Pacific Properties (NYSE:HPP) President Purchases $43,650.00 in Stock

3 Magnificent Stocks to Buy Before 2027 and Hold for a Decade

'Scrooge' collects $19M, finds weekend receipts surprisingly festive

‘We had the worst fight’: I want my husband to retire at 65, but I don’t want to lose his $280,000 salary. Is that unreasonable?

Prediction: When Will Bitcoin Get Back to Its All-Time High?

Veteran trader warns Bitcoin's record may outlive him